Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Medical Breakthrough Stocks Under $1: OCGN, VERO, RSCI, VTAK, ENVB

Ocugen Inc. (NASDAQ: OCGN) emerges as a noteworthy biotech stock for investors to monitor in upcoming trading sessions. On February 22, 2024, Ocugen Inc. reported the successful completion of the initial cohort in the Phase 1/2 GARDian clinical trial for its OCU410ST product. This product, a modifier gene therapy candidate, aims to address Stargardt disease, an orphan blindness condition affecting approximately 35,000 individuals solely in the United States. Dr. Arun Upadhyay, Ocugen’s Head of Research and Development and Chief Scientific Officer highlighted this achievement as a significant clinical milestone for the company. OCU410ST represents a pioneering, potentially one-time therapy for Stargardt disease sufferers. With a surge in after-hours trading on February 26, 2024, keeping a close watch on Ocugen's stock performance could prove prudent. 

Venus Concept Inc. (NASDAQ: VERO), a leading global provider of medical aesthetic technology, revealed on February 23, 2024, that it had engaged in a registered direct offering, adhering to NASDAQ regulations regarding market pricing. Under this agreement, the company plans to offer 817,748 shares of its common stock at a price of $$1.465 per share. Simultaneously, Venus Concept Inc. will conduct a private placement, issuing unregistered warrants enabling the purchase of up to 817,748 shares of common stock at an exercise price of $1.34 per share. These warrants will be immediately exercisable upon issuance and will remain valid for a period of five years from the date of issuance. 

Redwood Scientific Technologies Inc. (OTC: RSCI) The company witnessed a remarkable uptick in its stock performance across a span of 5 trading sessions, achieving an impressive gain of 97.95%. Concurrently, the trading volume for the stock exhibited significant vigor. On February 6, 2024, it was revealed that Redwood Scientific Technologies Inc. had entered a partnership with Jeeva Clinical Trials. This collaboration is geared towards initiating clinical effectiveness studies for Redwood Scientific Technologies’ TBX-free oral strips, designed to aid in smoking and e-cigarette cessation efforts. 

Catheter Precision (NYSE American: VTAK), a leading technology firm specializing in state-of-the-art electrophysiology techniques for treating cardiac arrhythmias, introduced its LockeT suture closure device at the upcoming International Symposium on Left Atrial Appendage, scheduled for March 1-2, 2024, at the Intercontinental New York Times Square. This event is poised to draw worldwide attention and provide essential education for healthcare professionals in cardiology, electrophysiology, and internal medicine. Additionally, Catheter Precision Inc. showcased its latest innovations at the AF Symposium conference held from February 1-3, 2024, in Boston, Massachusetts. Catheter Precision Inc. (NYSE American: VTAK) gained recognition as a prominent innovator in the swiftly growing medical manufacturing sector, notably highlighted in a feature in "MedTech Outlook." With a focus on electrophysiology (EP) technology, delve into the complete interview in "MedTech Outlook" for thorough insights, and also explore the EP Lab Digest Case Study

Enveric Biosciences (NASDAQ: ENVB) operates as a biotechnology company dedicated to advancing neuroplastogenic small-molecule therapeutics aimed at addressing conditions such as anxiety, depression, and addiction-related disorders. On February 23, 2024, Enveric Biosciences disclosed an arrangement to divest a specific cancer-focused patent portfolio, the financial terms of which were not disclosed. Despite this transaction, the company affirmed its commitment to advancing EB 003, its primary candidate, through ongoing investment and research efforts.

 

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com


Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.